Download PDF
Aktuelle Urol 2024; 55(06): 520-527
DOI: 10.1055/a-2422-0354
Übersicht

Neue Tumormarker bei Hodentumoren – im hier und jetzt und in der Zukunft

New tumor markers for testicular cancer – in the here and now and in the future
Justine Schoch
1   Klinik für Urologie, Bundeswehrzentralkrankenhaus Koblenz, Koblenz, Germany (Ringgold ID: RIN39540)
,
Hans Schmelz
1   Klinik für Urologie, Bundeswehrzentralkrankenhaus Koblenz, Koblenz, Germany (Ringgold ID: RIN39540)
,
Klaus-Peter Dieckmann 
2   Urologie, Asklepios Klinik Altona, Hamburg, Germany (Ringgold ID: RIN14917)
,
Tim Nestler 
1   Klinik für Urologie, Bundeswehrzentralkrankenhaus Koblenz, Koblenz, Germany (Ringgold ID: RIN39540)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Keimzelltumore sind die häufigsten Tumorentitäten bei jungen Männern. Seit der Einführung der platinbasierten Chemotherapie in den 1970er-Jahren können die meisten Patienten trotz der Aggressivität der Keimzelltumoren kurativ behandelt werden. Für Diagnostik, Therapiemonitoring und Nachsorge werden möglichst optimale Serumtumormarker benötigt, an die hohe Anforderungen gestellt werden. Die konventionellen Hodentumormarker humanes Choriongonadotropin (hCG), Alpha-Fetoprotein (AFP) und Laktatdehydrogenase (LDH) werden diesen Anforderungen nur mit einer unzureichenden Sensitivität gerecht (30–70%). Die in den letzten Jahrzehnten untersuchten Marker wie PLAP, CEA und NSE haben sich nicht durchgesetzt. Aktuell wird besonders die miRNA-371 erforscht. Gesicherte Erkenntnisse liegen vor für das initiale Staging mit deutlich besseren Spezifitäten der miRNA-371 im Vergleich zu den konventionellen Tumormarkern. Für weitere mögliche klinische Einsatzgebiete wie der Nachsorge, dem Therapiemonitoring oder bei Residualtumoren erfolgen weitere prospektive Studien, um auch hier das revolutionäre Potenzial der miRNA-371 zu untersuchen. Weiterhin wird aktuell an zirkulierenden Tumorzellen (CTCs) und zellfreier DNA (cfNA) in verschiedenen Anwendungsgebieten geforscht. In Bezug auf Keimzelltumore des Hodens stehen diese Analysen jedoch noch am Anfang, aber man erhofft sich hiervon eine weitere suffiziente Möglichkeit Serumtumormarker einzusetzen.

Abstract

Germ cell tumors of the testis are the most common tumor entities in young men. Since the introduction of platinum-based chemotherapy in the 1970s, most patients can be cured despite the aggressiveness of germ cell tumors. Optimal serum tumor markers are required for diagnostics, therapy monitoring and aftercare, and these are subject to high requirements. The conventional testicular tumor markers human chorionic gonadotropin (hCG), alpha fetoprotein (AFP) and lactate dehydrogenase (LDH) only meet these requirements with insufficient sensitivity (30–70%). The markers investigated in recent decades, such as PLAP, CEA and NSE, have not become established. Currently, miRNA-371 is being researched in particular. Reliable findings are available for initial staging with significantly better specificities of miRNA-371 compared to conventional tumor markers. Further prospective studies are being conducted for other possible clinical applications, such as follow-up care, therapy monitoring or residual tumors, in order to investigate the revolutionary potential of miRNA-371 in these areas as well. Research is also currently being conducted on circulating tumor cells (CTCs) and cell-free DNA (cfNA) in various areas of application. With regard to germ cell tumors of the testis, however, these analyses are still in their infancy, but it is hoped that this will provide a further sufficient opportunity to use serum tumor markers.

Schlüsselwörter

Hodentumor - Keimzelltumor - Tumormarker - miR371

Keywords

Testicual Cancer - Germ Cell Tumor - Tumor marker - miR371


Publication History

Received: 12 June 2024

Accepted after revision: 20 September 2024

Article published online:
23 October 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens (Version 1.1, 2020).
    PubMed
  • 2 Chovanec M, Cheng L. Advances in diagnosis and treatment of testicular cancer. BMJ 2022; 379: e070499
    CrossrefPubMedSearch in Google Scholar
  • 3 International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603
    CrossrefPubMedSearch in Google Scholar
  • 4 Kliesch S, Schmidt S, Wilborn D. et al. Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urol Int 2021; 105: 169-180
    CrossrefPubMedSearch in Google Scholar
  • 5 Paffenholz P, Heidegger IM, Kuhr K. et al. Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival. Clin Genitourin Cancer 2018; 6: e243-e250
    CrossrefPubMedSearch in Google Scholar
  • 6 Berney DM, Cree I, Rao V. et al. An introduction to the WHO 5th edition 2022 classification of testicular tumours. Histopathology 2022; 81: 459-466
    CrossrefPubMedSearch in Google Scholar
  • 7 Fankhauser CD, Gerke TA, Roth L. et al. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment. J Cancer Res Clin Oncol 2019; 145: 781-785
    CrossrefPubMedSearch in Google Scholar
  • 8 Majewski M, Paffenholz P, Ruf C. et al. Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment. Cancer Med 2023; 12: 16829-16836
    CrossrefPubMedSearch in Google Scholar
  • 9 Lange PH, Winfield HN. Biological markers in urologic cancer. Cancer 1987; 60 (Suppl. 03) 464-472
    CrossrefPubMedSearch in Google Scholar
  • 10 Fizazi K, Culine S, Kramar A. et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004; 22: 3868-3876
    CrossrefPubMedSearch in Google Scholar
  • 11 Sturgeon JF, Moore MJ, Kakiashvili DM. et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol 2011; 59: 556-562
    CrossrefPubMedSearch in Google Scholar
  • 12 Zondek B. Maligne Hodentumoren und Hypophysenvorderlappenhormone. Hormonale Diagnostik aus Harn, Hydrocelenflüssigkeit und Tumorgewebe. Klinische Wochenschr 1932; 11: 274-279
    PubMedSearch in Google Scholar
  • 13 Javadpour N, McIntire KR, Waldmann TA. Immunochemical determination of human chorionic gonadotropin and alpha-fetoprotein in sera and tumors of patients with testicular cancer. Natl Cancer Inst Monogr 1978; 49: 209-213
    PubMedSearch in Google Scholar
  • 14 Norgaard-Pedersen B, Schultz HP, Arends J. et al. Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976–1980. Acta Radiol Oncol 1984; 23: 287-294
    CrossrefPubMedSearch in Google Scholar
  • 15 Dieckmann KP, Simonsen-Richter H, Kulejewski M. et al. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment. Biomed Res Int 2019; 2019: 5030349
    CrossrefPubMedSearch in Google Scholar
  • 16 Egan J, Salari K. Biomarkers in Testicular Cancer: Classic Tumor Markers and Beyond. Urol Clin North Am 2023; 50: 133-143
    CrossrefPubMedSearch in Google Scholar
  • 17 Mir MC, Pavan N, Gonzalgo ML. Current Clinical Applications of Testicular Cancer Biomarkers. Urol Clin North Am 2016; 43: 119-125
    CrossrefPubMedSearch in Google Scholar
  • 18 Takizawa A, Kawai K, Kawahara T. et al. The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor. J Cancer Res Clin Oncol 2018; 144: 109-115
    CrossrefPubMedSearch in Google Scholar
  • 19 Szymendera JJ, Zborzil J, Sikorowa L. et al. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors. Oncology 1983; 40: 1-10
    CrossrefPubMedSearch in Google Scholar
  • 20 Kuzmits R, Schernthaner G, Krisch K. Serum neuron-specific enolase. A marker for responses to therapy in seminoma. Cancer 1987; 60: 1017-1021
    CrossrefPubMedSearch in Google Scholar
  • 21 Lajer H, Daugaard G, Andersson AM. et al. Clinical use of serum TRA-1–60 as tumor marker in patients with germ cell cancer. Int J Cancer 2002; 100: 244-246
    CrossrefPubMedSearch in Google Scholar
  • 22 Neumann A, Keller T, Jocham D. et al. Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer. Aktuelle Urol 2011; 42: 311-315
    PubMedSearch in Google Scholar
  • 23 Nielsen OS, Munro AJ, Duncan W. et al. Is placental alkaline phosphatase (PLAP) a useful marker for seminoma?. Eur J Cancer 1990; 26: 1049-1054
    CrossrefPubMedSearch in Google Scholar
  • 24 Pottek T, Muller M, Blum T. et al. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 2000; 20: 5029-5033
    PubMedSearch in Google Scholar
  • 25 Lobo J, Gillis AJM, Jeronimo C. et al. Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic. Int J Mol Sci 2019; 20: 258
    CrossrefPubMedSearch in Google Scholar
  • 26 Eini R, Dorssers LC, Looijenga LH. Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer. Int J Dev Biol 2013; 57: 319-332
    CrossrefPubMedSearch in Google Scholar
  • 27 Suh MR, Lee Y, Kim JY. et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol 2004; 270: 488-498
    CrossrefPubMedSearch in Google Scholar
  • 28 Gillis AJ, Stoop HJ, Hersmus R. et al. High-throughput microRNAome analysis in human germ cell tumours. J Pathol 2007; 213: 319-328
    CrossrefPubMedSearch in Google Scholar
  • 29 Syring I, Bartels J, Holdenrieder S. et al. Circulating serum miRNA (miR-367–3p, miR-371a-3p, miR-372–3p and miR-373–3p) as biomarkers in patients with testicular germ cell cancer. J Urol 2015; 193: 331-337
    CrossrefPubMedSearch in Google Scholar
  • 30 Agthoven T van, Looijenga LHJ. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test). Oncotarget 2017; 8: 58037-58049
    CrossrefPubMedSearch in Google Scholar
  • 31 Dieckmann KP, Radtke A, Spiekermann M. et al. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. Eur Urol 2017; 71: 213-220
    CrossrefPubMedSearch in Google Scholar
  • 32 Radtke A, Cremers JF, Kliesch S. et al. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?. J Cancer Res Clin Oncol 2017; 143: 2383-2392
    CrossrefPubMedSearch in Google Scholar
  • 33 Nestler T, Schoch J, Belge G. et al. MicroRNA-371a-3p-The Novel Serum Biomarker in Testicular Germ Cell Tumors. Cancers (Basel) 2023; 15: 3944
    CrossrefPubMedSearch in Google Scholar
  • 34 Sharbidre KG, Lockhart ME. Imaging of scrotal masses. Abdom Radiol (NY) 2020; 45: 2087-2108
    CrossrefPubMedSearch in Google Scholar
  • 35 Belge G, Dumlupinar C, Nestler T. et al. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study. Clin Cancer Res 2024; 30: 404-412
    CrossrefPubMedSearch in Google Scholar
  • 36 Lobo J, Leao R, Gillis AJM. et al. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol 2021; 4: 483-491
    CrossrefPubMedSearch in Google Scholar
  • 37 Radtke A, Hennig F, Ikogho R. et al. The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1. Urol Int 2018; 100: 470-475
    CrossrefPubMedSearch in Google Scholar
  • 38 Rosas Plaza X, Agthoven T van, Meijer C. et al. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy. Cells 2019; 8: 1221
    CrossrefPubMedSearch in Google Scholar
  • 39 Umbreit EC, McIntosh AG, Suk-Ouichai C. et al. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer 2020; 126: 4878-4885
    CrossrefPubMedSearch in Google Scholar
  • 40 Nestler T, Paffenholz P, Pfister D. et al. Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection. J Urol 2024; 211: 426-435
    CrossrefPubMedSearch in Google Scholar
  • 41 Daneshmand S, Albers P, Fossa SD. et al. Contemporary management of postchemotherapy testis cancer. Eur Urol 2012; 62: 867-876
    CrossrefPubMedSearch in Google Scholar
  • 42 Paffenholz P, Nestler T, Hoier S. et al. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer. Urol Oncol 2019; 37: 809 e9–e18
    CrossrefPubMedSearch in Google Scholar
  • 43 Dieckmann KP, Radtke A, Geczi L. et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol 2019; 37: 1412-1423
    CrossrefPubMedSearch in Google Scholar
  • 44 Dieckmann KP, Grobelny F, Soave A. et al. Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours. Eur Urol Focus 2024;
    CrossrefPubMedSearch in Google Scholar
  • 45 EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN: 978-94-92671-19-6
  • 46 Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med 2018; 379: 1754-1765
    CrossrefPubMedSearch in Google Scholar
  • 47 Ellinger J, Wittkamp V, Albers P. et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol 2009; 181: 363-371
    CrossrefPubMedSearch in Google Scholar
  • 48 Krasic J, Skara L, Bojanac AK. et al. The utility of cfDNA in TGCT patient management: a systematic review. Ther Adv Med Oncol 2022; 14 17588359221090365
    CrossrefPubMedSearch in Google Scholar
  • 49 Bettegowda C, Sausen M, Leary RJ. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6: 224ra24
    CrossrefPubMedSearch in Google Scholar
  • 50 Bart J, Groen HJ, Graaf WT van der. et al. An oncological view on the blood-testis barrier. Lancet Oncol 2002; 3: 357-363
    CrossrefPubMedSearch in Google Scholar
  • 51 Agashe R, Kurzrock R. Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers (Basel) 2020; 12: 2361
    CrossrefPubMedSearch in Google Scholar
  • 52 Banko P, Lee SY, Nagygyorgy V. et al. Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol 2019; 12: 48
    CrossrefPubMedSearch in Google Scholar
  • 53 Hao SJ, Wan Y, Xia YQ. et al. Size-based separation methods of circulating tumor cells. Adv Drug Deliv Rev 2018; 125: 3-20
    CrossrefPubMedSearch in Google Scholar
  • 54 Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol 2022; 15: 131
    CrossrefPubMedSearch in Google Scholar
  • 55 Su DW, Nieva J. Biophysical technologies for understanding circulating tumor cell biology and metastasis. Transl Lung Cancer Res 2017; 6: 473-485
    CrossrefPubMedSearch in Google Scholar
  • 56 Plaks V, Koopman CD, Werb Z. Cancer. Circulating tumor cells. Science 2013; 341: 1186-1188
    CrossrefPubMedSearch in Google Scholar
  • 57 Nastaly P, Ruf C, Becker P. et al. Circulating tumor cells in patients with testicular germ cell tumors. Clin Cancer Res 2014; 20: 3830-3841
    CrossrefPubMedSearch in Google Scholar